http://www.jcps.ac.cn

Journal of Chinese Pharmaceutical Sciences ›› 2015, Vol. 24 ›› Issue (1): 34-39.DOI: 10.5246/jcps.2015.01.004

• Original articles • Previous Articles     Next Articles

Targeting glioblastoma cancer stem cell marker CD133 by heptapeptide-modified DSPE-PEG micelles

Jingda Wang, Bing He, Wenbing Dai, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang*   

  1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2014-07-19 Revised:2014-08-05 Online:2015-01-15 Published:2014-08-20
  • Contact: Tel.: 86-10-82802791
  • Supported by:

    The Key Program of National Science Foundation (Grant No. 81130059), the National Basic Research Program of China (Grant No. 973 program, 2013CB932501).

Abstract:

Cancer stem cells have become the new target of chemotherapy with specific cell marker. CD133 is shown to be highly expressed in glioma cancer stem cells. In this study, a drug delivery system is designed to target CD133 by a seven amino acid peptide (TR peptide), which is capable to specifically bind to CD133. First, TR was conjugated to DSPE-PEG and coumarin-6 was loaded into the DSPE-PEG micelles. Then fluorescence-activated cell sorting (FACS) and tumorsphere culture were conductedto isolate cancer stem cells in C6 cells. The enhanced uptake of micelles was observed by confocal microscopy and flow cytometry,suggesting that TR peptide-modified micelles may exhibit better anti-cancer efficacy by targeting CD133+ glioma stem cells. In conclusion, TR peptide-modified micelles may provide new strategy to achieve enhanced specificity to CD133+ glioma stem cells.

Key words: Cancer stem cell, CD133, TR peptide, Micelle, Tumorsphere, FACS

CLC Number: 

Supporting: